Patents by Inventor Andre COHNEN

Andre COHNEN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • TYPE V RNA PROGRAMMABLE ENDONUCLEASE SYSTEMS
    Publication number: 20240141312
    Abstract: Described herein are novel systems for targeting, editing or manipulating DNA in a cell or cell free environment, using novel type V B-GEn.1 or B-GEn.2 nucleases and variants thereof, as well as methods and kits for manipulating DNA. Further disclosed are novel and improved single guide RNAs.
    Type: Application
    Filed: June 9, 2022
    Publication date: May 2, 2024
    Applicant: Bayer Aktiengesellschaft
    Inventors: Andre COHNEN, Florian RICHTER, Philipp KNYPHAUSEN, Andreas NEERINCX, Saskia Diana MARKERT, Christien BEDNARSKI, Sören TURAN
  • CRISPR-CAS12A DIRECTED RANDOM MUTAGENESIS AGENTS AND METHODS
    Publication number: 20230235319
    Abstract: Disclosed are new nucleic acid base-editing systems comprising fusion proteins comprising a) an RNA-programmable nucleic acid recognition module or other suitable nucleic acid recognition module, b) a light inducible reactive oxygen generator. Further disclosed are methods and kits to modify or mutagenize a target DNA region in prokaryotic or eukaryotic cells or organisms.
    Type: Application
    Filed: June 9, 2021
    Publication date: July 27, 2023
    Inventors: Philipp Knyphausen, Brian Vogler, Wayne Coco, Andre Cohnen, Florian Richter, Damian Curtis
  • RNA-programmable endonuclease systems and their use in genome editing and other applications
    Patent number: 11578323
    Abstract: Aspects of this invention inter alia relate to novel systems for targeting, editing or manipulating DNA in a cell, comprising one or more heterologous vector(s) encoding a SluCas9 nuclease from Staphylococcus lugdunensis or variants thereof, and one or more guide RNAs (gRNAs), or a SluCas9 nuclease or variant thereof and one or more gRNAs.
    Type: Grant
    Filed: December 14, 2018
    Date of Patent: February 14, 2023
    Assignees: BAYER HEALTHCARE LLC, CRISPR THERAPEUTICS AG
    Inventors: Andre Cohnen, Moritz Schmidt, Wayne Coco, Ashish Gupta, Jan Tebbe, Cindy Schulenburg, Christian Pitzler, Michael Biag Gamalinda, Sabine Jach, Florian Richter, Anup Arumughan, Corinna Saalwächter
  • NOVEL HIGH FIDELITY RNA-PROGRAMMABLE ENDONUCLEASE SYSTEMS AND USES THEREOF
    Publication number: 20220145274
    Abstract: Described herein are novel systems for targeting, editing or manipulating DNA in a cell, using novel M-SmallCas9 nucleases and variants thereof. The M-SmallCas9 nucleases are derived from wildtype or parental small type II CRISPR Cas9 endonucleases, and display improved fidelity compared to parental type II CRISPR Cas9 enzymes in combination with a simple PAM sequences and are small endonuclease size.
    Type: Application
    Filed: March 12, 2020
    Publication date: May 12, 2022
    Inventors: Moritz Schmidt, Philipp Knyphausen, Christina Galonska, Wayne Coco, Andre Cohnen
  • NOVEL RNA-PROGRAMMABLE ENDONUCLEASE SYSTEMS AND USES THEREOF
    Publication number: 20210054353
    Abstract: Aspects of this invention, inter alia, relate to novel systems for targeting, editing or manipulating DNA in a cell, using novel synthetic RNA-guided nucleases (sRGNs). The sRGNs are derived from wildtype or parental small type II CRISPR Cas9 endonucleases.
    Type: Application
    Filed: March 19, 2019
    Publication date: February 25, 2021
    Inventors: Andre COHNEN, Moritz SCHMIDT, Wayne COCO, Michael Biag GAMALINDA, Ashish GUPTA, Christian PITZLER, Florian RICHTER, Jan TEBBE, Christopher CHENG, Ryo TAKEUCHI, Caroline W. REISS
  • NOVEL RNA-PROGRAMMABLE ENDONUCLEASE SYSTEMS AND THEIR USE IN GENOME EDITING AND OTHER APPLICATIONS
    Publication number: 20200385720
    Abstract: Aspects of this invention inter alia relate to novel systems for targeting, editing or manipulating DNA in a cell, comprising one or more heterologous vector(s) encoding a SluCas9 nuclease from Staphylococcus lugdunensis or variants thereof, and one or more guide RNAs (gRNAs), or a SluCas9 nuclease or variant thereof and one or more gRNAs.
    Type: Application
    Filed: December 14, 2018
    Publication date: December 10, 2020
    Inventors: Andre COHNEN, Moritz SCHMIDT, Wayne COCO, Ashish GUPTA, Jan TEBBE, Cindy SCHULENBURG, Christian PITZLER, Michael Biag GAMALINDA, Sabine JACH, Florian RICHTER, Anup ARUMUGHAN, Corinna SAALWÄCHTER